Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Candida glabrata Infection: A Case Report.
Alina AdeelMing D QuEfaza SiddiquiStuart M LevitzRichard T EllisonPublished in: Open forum infectious diseases (2021)
Rezafungin is a semisynthetic, long-acting echinocandin with broad-spectrum activity against many Candida species and Aspergillus species, including a subset of drug-resistant strains. It is currently in phase III trials and was found to be safe and effective for the treatment of candidemia and/or invasive Candida infections in a phase II trial. However, there are no long-term safety or efficacy data. We report on the successful ongoing compassionate use of rezafungin obtained through expanded access for over 1 year in a patient with a multidrug-resistant Candida glabrata mediastinal infection from a vascular graft infection and retained foreign material.
Keyphrases
- candida albicans
- drug resistant
- multidrug resistant
- biofilm formation
- phase iii
- acinetobacter baumannii
- open label
- gram negative
- clinical trial
- escherichia coli
- randomized controlled trial
- stem cells
- klebsiella pneumoniae
- pseudomonas aeruginosa
- double blind
- electronic health record
- case report
- staphylococcus aureus
- machine learning
- big data
- placebo controlled
- phase ii
- artificial intelligence
- mesenchymal stem cells
- replacement therapy
- combination therapy